Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone for immune checkpoint inhibitor–associated interstitial lung disease
jRCTs031210327Phase 2Recruiting
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prednisolone in interstitial lung disease (ILD), alveolitis, bronchial carcinoma and 1 more (2 arms). Primary endpoint: Improvement in CTCAE v5.0 pneumonitis grade at day 14. Started Jan 2022; status: recruiting.
02
Drugs
prednisolone
03
Conditions
interstitial lung disease (ILD)alveolitisbronchial carcinomamesothelioma
Beyond the preview
Go deeper on jRCTs031210327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210327.